0.180
0.04 (28.57%)
| Previous Close | 0.140 |
| Open | 0.142 |
| Volume | 805,051 |
| Avg. Volume (3M) | 7,202,718 |
| Market Cap | 5,280,160 |
| Price / Earnings (TTM) | 0.003 |
| Price / Earnings (Forward) | 0.370 |
| Price / Sales | 660.53 |
| Price / Book | 0.610 |
| 52 Weeks Range | |
| Earnings Date | 18 Aug 2025 - 22 Aug 2025 |
| Diluted EPS (TTM) | -6,321.50 |
| Total Debt/Equity (MRQ) | 15.34% |
| Current Ratio (MRQ) | 0.250 |
| Operating Cash Flow (TTM) | -14.86 M |
| Levered Free Cash Flow (TTM) | -13.41 M |
| Return on Assets (TTM) | -53.20% |
| Return on Equity (TTM) | -124.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Windtree Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.01% |
| % Held by Institutions | 1.39% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Sep 2025 | Announcement | Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting |
| 11 Aug 2025 | Announcement | Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 |
| 05 Aug 2025 | Announcement | Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients |
| 29 Jul 2025 | Announcement | Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption |
| 24 Jul 2025 | Announcement | Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy |
| 22 Jul 2025 | Announcement | Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |